Compare ATEN & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATEN | AMPH |
|---|---|---|
| Founded | 2004 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2014 | 2005 |
| Metric | ATEN | AMPH |
|---|---|---|
| Price | $20.39 | $18.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | $23.75 | ★ $30.29 |
| AVG Volume (30 Days) | ★ 760.5K | 499.1K |
| Earning Date | 05-04-2026 | 06-01-2026 |
| Dividend Yield | ★ 1.17% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.57 | ★ 2.03 |
| Revenue | $235,429,000.00 | ★ $719,887,000.00 |
| Revenue This Year | $12.96 | $7.34 |
| Revenue Next Year | $10.18 | $4.81 |
| P/E Ratio | $35.82 | ★ $9.54 |
| Revenue Growth | ★ 2.36 | N/A |
| 52 Week Low | $13.81 | $18.94 |
| 52 Week High | $21.31 | $31.26 |
| Indicator | ATEN | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 58.46 | 24.09 |
| Support Level | $17.04 | N/A |
| Resistance Level | $21.31 | $28.56 |
| Average True Range (ATR) | 0.64 | 1.19 |
| MACD | 0.02 | -0.89 |
| Stochastic Oscillator | 72.00 | 3.08 |
A10 Networks Inc is a provider of security and infrastructure solutions for on-premises, hybrid cloud, and edge-cloud environments of its multinational enterprise, communication, cloud and web service provider customers who strive to provide business-critical applications and networks that are secure, available, and efficient. As cyber-attacks increase in volume and complexity, the company integrates security and artificial intelligence (AI) enabled capabilities in its solutions that enable its customers to continue to adapt to market trends in hybrid cloud, AI-ready data centers and the ever-increasing need for high-performance, high availability and low latency. The company generates the maximum of its revenue from Americas.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.